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The secretion inhibitor Exo2 perturbs trafficking of Shiga toxin between
endosomes and the trans-Golgi network
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The small-molecule inhibitor Exo2 {4-hydroxy-3-methoxy-
(5,6,7,8-tetrahydrol[1]benzothieno[2,3-d]pyrimidin-4-yl)hydraz-
one benzaldehyde} has been reported to disrupt the Golgi
apparatus completely and to stimulate Golgi–ER (endoplasmic
reticulum) fusion in mammalian cells, akin to the well-character-
ized fungal toxin BFA (brefeldin A). It has also been reported
that Exo2 does not affect the integrity of the TGN (trans-Golgi
network), or the direct retrograde trafficking of the glycolipid-
binding cholera toxin from the TGN to the ER lumen. We have
examined the effects of BFA and Exo2, and found that both
compounds are indistinguishable in their inhibition of anterograde
transport and that both reagents significantly disrupt the mor-
phology of the TGN in HeLa and in BS-C-1 cells. However,
Exo2, unlike BFA, does not induce tubulation and merging of the
TGN and endosomal compartments. Furthermore, and in con-
trast with its effects on cholera toxin, Exo2 significantly perturbs
the delivery of Shiga toxin to the ER. Together, these results
suggest that the likely target(s) of Exo2 operate at the level of
the TGN, the Golgi and a subset of early endosomes, and thus
Exo2 provides a more selective tool than BFA for examining
membrane trafficking in mammalian cells.
Key words: brefeldin A (BFA), Exo2, Golgi, membrane traffic,
secretory pathway, Shiga toxin (STx).
INTRODUCTION
Although much of our knowledge of the secretory pathway comes
from genetic or biochemical experiments [1,2], small-molecule
inhibitors have also proven to be extremely useful tools for
studying this pathway. Perhaps the best example is the fungal
isoprenoid metabolite BFA (brefeldin A), which causes rapid
dissociation of COPI (coatomer protein I) coats from Golgi mem-
branes [3,4] and consequent tubulation and subsequent merging of
Golgi membranes with those of the ER (endoplasmic reticulum)
[5,6]. BFA also induces very rapid and dramatic tubulation of
EEs (early endosomes) and causes a redistribution of the TGN
(trans-Golgi network) and endosomes, including microtubule-
dependent fusion of the TGN and EEs [7–9]. Many of the effects of
BFA are mediated by its inhibition of GEFs (guanine-nucleotide-
exchange factors) that act on the small GTPases of the ARF (ADP-
ribosylation factor) family [10–12]. BFA acts as an interfacial
inhibitor [13–15], binding and stabilizing an abortive complex of
ARF-GEF–ARF1–GDP, thereby preventing GDP/GTP exchange
and inhibiting ARF1 activation [16].
Previous chemical genetics approaches have identified further
inhibitors of secretory pathway function that appear to cause
similar effects to those of BFA. Two inhibitors, termed Exo1 [2-(4-
fluorobenzoylamino)-benzoic acid methyl ester] [17] and
Exo2 {4-hydroxy-3-methoxy-(5,6,7,8-tetrahydrol[1]benzothieno-
[2,3-d]pyrimidin-4-yl)hydrazone benzaldehyde} [18], show little
structural similarity to BFA but, importantly, they demonstrate
some near-identical effects in a number of assays. Although
the targets of Exo1 and Exo2 remain unknown, Exo1 has been
shown not to interfere with GEF-stimulated GDP/GTP exchange
on ARF; it somehow interferes with the ARF-dependent GTP
hydrolysis step [17]. Nothing is known about the precise target(s)
of Exo2, but, as with Exo1, a description of the phenotype
promoted by this inhibitor will help to guide and focus future
studies into finding this protein. It has already been reported that
Exo2 blocks secretory cargo exit from the ER and disrupts the
Golgi apparatus, but does not affect the morphology of the TGN
[18]. Since the trafficking of the glycolipid-binding CTx (cholera
toxin) from the cell surface to the ER remained unaffected in
Exo2-treated cells, as did continued sulfation of a modified CTx
subunit that was believed to occur during passage through the
TGN, an alternative pathway for the direct transport of CTx from
the TGN to the ER has been proposed [18]. These results are
significant in that they define a retrograde-trafficking pathway
based on the continued integrity of the TGN in the presence of
Exo2. This leads to the possibility of exploiting the different
effects of BFA and Exo2 to examine such a pathway more fully.
In the present paper, using a different set of organelle markers
and the well-characterized lipid-binding STx (Shiga toxin), we
have examined the effects of BFA and Exo2 in mammalian
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cells. Using a combination of fixed- and live-cell imaging and
functional examination of retrograde-trafficking pathways, we
confirm that these two compounds have indistinguishable effects
on anterograde transport from the ER-to-Golgi and on the
Golgi. However, unlike BFA, Exo2 does not induce tubulation
of endosomal compartments. Moreover, and in contrast with
results published previously [18], we find that Exo2 disrupts the
morphology of the TGN, and that the retrograde transport of STx
is severely compromised in two toxin-sensitive cell lines. These
results reveal subtle but important differences in the effects of
BFA and Exo2 on endomembrane organization and function, and
on the trafficking of different lipid-binding toxins.
EXPERIMENTAL
Materials
For immunofluorescence studies, HeLa (A.T.C.C. CCL-2) cells
were grown on glass-bottomed dishes (MatTek) or 22 mm-dia-
meter coverslips in DMEM (Dulbecco’s modified Eagle’s
medium; Life Technologies)/FCS (foetal calf serum) medium sup-
plemented with 10% (v/v) FCS and 1% L-glutamine. Rabbit
polyclonal anti-giantin antibody was from Covance. Mouse
monoclonal anti-GM130 (cis-Golgi matrix protein of 130 kDa),
mouse monoclonal anti-EEA1 (early endosome antigen 1)
and mouse monoclonal anti-calnexin antibodies were from
BD Transduction Laboratories. Sheep polyclonal anti-TGN46
antibody was from AbD Serotec and mouse monoclonal anti-
ERGIC (ER–Golgi intermediate compartment)-53 antibody was
from Alexis Biochemicals. Mouse monoclonal anti-GalT (galac-
tosyltransferase) antibody was from CellMAb. Monoclonal
mouse anti-CD63 antibody (Biogenesis) was a gift from
Dr Harry Mellor (Department of Biochemistry, University of
Bristol, Bristol, U.K.). Alexa Fluor® dye-labelled secondary
antibodies (anti-rabbit, anti-mouse and anti-sheep IgG antibodies;
all highly cross-adsorbed), Alexa Fluor® 568-labelled transferrin,
mouse monoclonal anti-golgin-97 antibody (clone CDF4),
mouse monoclonal anti-TfR (transferrin receptor) antibody and
LysoTracker Red were from Invitrogen.
Cytotoxicity measurements
Cells were seeded at 2 × 104 cells per well in 96-well plates in
DMEM/FCS (HeLa and Vero cells), GMEM (Glasgow minimal
essential medium)/10% (v/v) FCS (BS-C-1 cells; A.T.C.C. CCL-
26) or 1:1 (v/v) DMEM/Ham’s F12 medium containing 5% (v/v)
FCS (T84 cells), grown overnight at 37 ◦C, washed with PBS and
were then incubated for 30 min at 37 ◦C in the appropriate growth
medium containing trafficking inhibitor (50 μM Exo2 and 0.05%
DMSO vehicle) or vehicle only (10 μg · ml−1 BFA and 0.5% etha-
nol vehicle). The cells were then incubated with graded dilutions
of STx in the relevant growth medium containing trafficking
inhibitor or vehicle as appropriate for 1, 2 or 4 h at 37 ◦C. Cyto-
toxicity was measured as the ability of cells to incorporate
[35S]methionine into acid-precipitable material after toxin treat-
ment, using an assay published previously [19]. IC50 values (in
ng · ml−1) were determined using a median-effect plot [20].
Immunofluorescence and live cell-imaging
Live and fixed cells were imaged using wide-field microscopy as
described previously [20a]. Where indicated, cells were treated
with nocodazole (5 μM; Sigma), BFA (10 μM; Sigma) or with
an equal volume of DMSO (vehicle only) for 1 h at 37 ◦C in
the appropriate culture medium. For immunofluorescence, cells
were fixed with methanol at −20 ◦C for 4 min, blocked using PBS
containing 3% (w/v) BSA and incubated with primary antibodies
[anti-EEA1 antibody (1:500 dilution), anti-CD63 antibody
(1:1000 dilution), anti-giantin antibody (1:2000 dilution), anti-
ERGIC-53 antibody (1:100 dilution), anti-Sec31A antibody
(1:100 dilution), anti-golgin-97 antibody (1:500 dilution), anti-
TGN46 antibody (1:500 dilution), anti-calnexin antibody (1:100
dilution), anti-GalT antibody (1:500 dilution), anti-TfR antibody
(1:500 dilution) and anti-COPI antibody (1:100 dilution)] for
1 h. LysoTracker Red was used following the manufacturer’s
instructions. For staining of EEA1, cells were fixed with 3.5%
(w/v) paraformaldehyde in PBS for 15 min at room temperature
(18–25 ◦C) and permeabilized by incubation with 0.1% Triton
X-100 in PBS for 5 min at room temperature. For CD63 staining,
paraformaldehyde-fixed cells were permeabilized with 0.5%
saponin in PBS for 5 min at room temperature, with all subsequent
steps performed in the presence of 0.1% saponin. Alexa
Fluor® 488-, Alexa Fluor® 568- or Alexa Fluor® 647-conju-
gated antibodies (anti-rabbit, anti-mouse and anti-sheep IgG anti-
bodies; 1:800 dilution) and Cy3 (indocarbocyanine)-labelled
antibody (1:500 dilution; Jackson ImmunoResearch) were used
as secondary antibodies. Alexa Fluor® 568-conjugated transferrin
was diluted in growth medium and added to cells at a final con-
centration of 10 μg · ml−1. Images and time-lapse sequences
were acquired 5 min after incubation with Alexa Fluor® 568-
conjugated transferrin. Wide-field images were acquired as
described previously [21]. Confocal sections were acquired using
a Leica TCS SP2 AOBS scanning-confocal microscope with illu-
mination from the 543 nm line of a HeNe laser (for Alexa Fluor®
568-conjugated transferrin) and 405 nm diode laser [for DAPI
(4′,6-diamidino-2-phenylindole)]. A pinhole size of 1 Airy disk
and a pixel size of 100 nm were used, and images were acquired
using the linear range of the detector. All images were pro-
cessed using Photoshop CS (Adobe), ImageJ [NIH (National
Institutes of Health)] and QuickTime Pro (Apple). Montages
were generated using Adobe Illustrator CS (Adobe). Movies were
compiled in QuickTime Pro using ‘Photo JPEG’ compression.
Sulfation analysis
Sulfation analysis was preformed as described previously [22].
Briefly, HeLa cells seeded at 2 × 105 cells per well in 12-well
plates were grown overnight at 37 ◦C, starved of sulfate for
90 min, with the last 30 min of this starvation period performed
in the presence of DMSO or 50 μM Exo2 in DMSO and, after
washing twice with PBS, STxBsulf [STxB (STx B chain) bearing
an accessible sulfation motif] was added and the cells were incub-
ated on ice for 30 min. After washing twice with PBS, 35SO4
(300 μCi · ml−1; Amersham Biosciences) in sulfate-free medium
containing DMSO or Exo2/DMSO as appropriate was added,
and STxBsulf was immunoprecipitated from detergent-soluble
extracts after 0, 20, 40, 60, 120, 180 and 240 min of incubation at
37 ◦C. In order to determine endogenous sulfation, sulfated pro-
teins in supernatants obtained after quantitative STxB immuno-
precipitation were precipitated with 10% (v/v) trichloroacetic
acid, retained on GF/C glass-fibre filtres (Whatman) and
scintillation counted.
Molecular cloning of TPST (tyrosylprotein sulfotransferase)–EGFP
(enhanced green fluorescent protein)
The TPST1 and TPST2 sequences were obtained from human
ESTs (expressed sequence tags) from the RZPD (Deutsches
Ressourcenzentrum fu¨r Genomforschung, Berlin, Germany;
GenBank® accession numbers NM_003596 and AF061254
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Figure 1 Synthesis of Exo2
The central thienopyrimidone unit (3) was constructed by condensation of cyanoamide with cyclohexanone in the presence of sulfur [27] to give aminothiophene (2) and cyclization with
formamide [28–30]. Chloride formation [31] and displacement gave the hydrazine (4) [32]. Condensation with vanillin (5) yielded Exo2 (1). The reactions in the scheme are: (a) piperidine/sulfur
(b) formamide/reflux, (c) phosphorus chloride oxide/dimethylaniline, (d) hydrazine hydrate in methanol, (e) vanillin in methanol.
respectively). TPST1–EGFP and TPST2–EGFP were obtained
by PCR using the following primers: plus strand, 5′-GGGGCT-
CGAGATGGTTGGAAAGCTGAAG-3′, and minus strand, 5′-
GGGGCTGCAGCTCCACTTGCTCAGTC-3′ for TPST1; and
plus strand, 5′-GGGGCTCGAGATGCGCCTGTCGGTGC-3′,
and minus strand, 5′-GGGGCTGCAGCGAGCTTCCTAAGTGG-
3′ for TPST2 (XhoI and PstI, restriction sites are underlined). PCR
products were purified and ligated into the pGEM-T-Easy vector
(Promega) following the manufacturer’s instructions. Positive
clones were digested with XhoI and PstI, and the fragments
obtained were inserted in the corresponding sites of pEGFP-N1
(Clontech). All constructs were verified by double-strand DNA
sequencing (MWG Biotech, Ebersburg, Germany). Two differ-
ences to the published sequence of TPST2 were identified
(276C>T and 1002T>C, relative to the start codon), but neither
of which affect the predicted protein sequence.
RESULTS
Exo2 treatment strongly protects cells against STx challenge
CTx and STx bind cell surface ganglioside GM1 and Gb3 (globo-
triaosylceramide) respectively and are delivered via EEs and the
TGN to the ER lumen, in association with detergent-resistant
microdomains, in a manner that is not dependent on either
KDEL receptors or COPI-transport intermediates [23–26]. When
human intestinal T84 cells were treated with Exo2, an inhibitor
of secretion isolated from the DIVERSetE chemical library
(Chembridge, San Diego, CA, U.S.A.) [17], they remained fully
sensitive to CTx, leading to a model whereby ER-trafficking
lipid-binding retrograde cargoes bypass the Golgi stack, moving
directly from the TGN to the ER [18]. To test this model further,
we therefore examined the effects of Exo2 on the uptake of STx.
We first manufactured Exo2 as shown in Figure 1. Briefly, the
central thienopyrimidone unit (3) was set up by condensation of
the cyanoamide with cyclohexanone in the presence of sulfur [27]
to give aminothiophene (2) and cyclization with formamide [28–
30]. Chloride formation [31] and displacement gave hydrazine
(4) [32]. Condensation with vanillin (5) yielded Exo2 (1). Stock
solutions were made at 100 mM in DMSO and stored in aliquots
at −20 ◦C.
Upon arrival into the ER, the enzymatic A1 chain of STx
retro-translocates across the ER membrane, entering the cytosol,
where it inactivates ribosomes and halts protein synthesis [33].
HeLa cells, pre-treated for 30 min with vehicle alone (0.05%
DMSO) or with 50 μM Exo2, were incubated with dilutions
of STx in growth medium containing DMSO or Exo2/DMSO
as appropriate for various times, and the remaining ability to
synthesize protein was measured (Figure 2A). Exo2 rendered cells
strongly resistant to STx challenge, but the level of resistance
varied with toxin exposure times (Figure 2C). Following short
toxin treatments (1 h), Exo2-treated cells were ∼150-fold more
resistant to STx than vehicle-treated cells that had been exposed to
the same doses of toxin. However, following 4 h exposure to toxin,
Exo2-treated cells were only ∼12-fold more resistant than
vehicle-treated cells.
STx is activated by furin, which nicks the intact STxA
polypeptide to generate a processed and activated A1 chain [34].
Since an Exo2-mediated block in anterograde transport might
alter the steady-state distribution of furin, the strong protective
effects observed may simply reflect an alteration in the trafficking
or replenishment rate of this facilitating enzyme. To preclude this
possibility, we pre-activated the toxin with trypsin (Figure 2B),
which nicks the A chain at its furin-sensitive site [34], and found
this made little difference to the protection observed (Figure 2C),
showing that the resistances observed are not caused by delayed
or incomplete processing of the toxin.
As a comparison, cells were pre-treated with 10 μg · ml−1
BFA (dissolved in ethanol) or the vehicle solvent alone (0.5%
ethanol), and then treated with dilutions of STx in growth medium
containing ethanol or ethanol/BFA as appropriate (Figure 2A).
BFA treatment resulted in protective effects against STx that
were too large to measure at the concentrations and times
used.
In African green-monkey-kidney-derived Vero and BS-C-1
cells, rates of CTx internalization and TGN and ER arrival were
unchanged following Exo2 treatment [18]. This contrasts with
the observations of the present paper when STx is applied to
HeLa cells. Therefore to check for a cell-type-dependent effect,
we tested the sensitivity of these kidney-derived cell lines to STx
when treated with Exo2. For Vero cells, which have a similar
sensitivity to STx as HeLa cells, the protective effect of Exo2
was very large, approx. 1200-fold for a 4 h toxin challenge
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Figure 2 Exo2 treatment protects HeLa and Vero cells against STx challenge
(A) HeLa cells pre-treated with DMSO, DMSO/Exo2, ethanol vehicle (ethanol) or ethanol/BFA for 30 min at 37◦C were treated with graded doses (20 μg · ml−1 to 0.05 ng · ml−1) of STx in medium
containing DMSO, DMSO/Exo2, ethanol, or ethanol/BFA as appropriate for 4 h (top panel), 2 h (middle panel) or 1 h (bottom panel), and their ability to synthesize proteins was subsequently
determined. Typical single assays are shown. , DMSO-treated; , DMSO/Exo2-treated; , ethanol-treated; , ethanol/BFA-treated. (B) STx was treated with trypsin (10 ng · ml−1) for various
lengths of timeas indicated (min) at 37◦C, and the STx A chain (black arrowhead) and nicked STx A1 chain (white arrowhead) products were separated by reducing-gel electrophoresis and revealed
by Coomassie Brilliant Blue staining. (C) DMSO- and DMSO/Exo2-pre-treated cells were challenged with graded doses of non-nicked (white bars) or pre-nicked (grey bars) STx as in (A) for the
times indicated (1, 2 or 4 h) at 37◦C after treatment with 10 ng · ml−1 trypsin for 30 min at 37◦C in medium containing DMSO or DMSO/Exo2 as appropriate, and the sensitivities to toxin (IC50)
were determined. The protective index is the ratio of IC50 Exo2-treated cells/IC50 control DMSO-treated cells. Results are means +− S.D. (n = 3) (D) Vero cells pre-treated with DMSO or DMSO/Exo2
for 30 min at 37◦C were treated with graded doses of STx in medium containing DMSO or DMSO/Exo2 as appropriate for the times indicated (1, 2 and 4 h) at 37◦C, and their ability to synthesize
proteins subsequently was determined. Typical single assays are shown., DMSO-treated;, DMSO/Exo2-treated.
(Figure 2D), and too large to measure at the concentrations of toxin
used here for 2 h and 1 h challenges. In contrast, BS-C-1 cells were
resistant to STx challenge at the times and concentrations of toxin
used here (results not shown). This was most likely the result of an
absence of functional Gb3 receptors. Indeed, in human intestinal
T84 cells, in which there is no detectable effect on the time course
of CTx action [18], it is known that only ∼5% of cells express
the STx receptor [35]. Accordingly, T84 cells were found to be
resistant to STx under the conditions of toxin challenge used here
(results not shown). Furthermore, butyric acid treatment, which
is known to sensitize some resistant cell lines to STx by inducing
synthesis of productive receptors [36,37], was also ineffective
when used on BS-C-1 and T84 cells (results not shown). Thus
neither BS-C-1 nor T84 cells can be used to test the effect of
Exo2 on the retrograde trafficking of STx.
We conclude that Exo2 treatment severely impairs, but does
not completely inhibit, the trafficking of STx to the ER in STx-
sensitive cells, even though it has no effect on CTx when tested
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Figure 3 Exo2 inhibits secretory transport of tsO45-G–YFP
HeLa cells were transfected with a plasmid encoding tsO45-G–YFP and incubated at 39.5◦C for 16 h to accumulate the protein in the ER. Cells were subsequently incubated at 39◦C for a further 2 h
in the presence of DMSO (Control), 10 μg · ml−1 BFA or 50 μM Exo2. Cells were then temperature-shifted to 32◦C to allow export of tsO45-G–YFP from the ER for the times indicated (0, 30, 60
and 120 min).
in these cells [18], and that the magnitude of the protective effect
varies with cell type.
Exo2 disperses the TGN in HeLa cells
The changing cytotoxicity profile seen with time in STx-sensitive
cells might indicate an incomplete effect of Exo2, such that after
longer toxin exposures (4 h), sufficient STx was able to reach the
ER to enter the cytosol and inhibit protein synthesis. Alternatively,
it may point to a gradual functional recovery of the toxin entry
pathway. To examine this further, we analysed the effects of Exo2
on secretion and the gross morphology of organelles known to
be required for normal STx retrograde trafficking. We initially
performed these experiments in HeLa cells, where the changing
profile of the effects of Exo2 with time of exposure is most readily
measured (Figure 2).
As expected, Exo2 acted as a secretion inhibitor, blocking the
ER-to-Golgi export of tsO45-G (temperature-sensitive vesicular-
stomatitis virus-G mutant)–YFP (yellow fluorescent protein), a
classic marker for secretory protein transport [38,39]. In control
cells, tsO45-G–YFP was released from the ER to the Golgi and
the cell surface after a temperature shift from 39.5 ◦C to 32 ◦C
(Figure 3). In contrast, in cells incubated with either 50 μM
Exo2 or 10 μg · ml−1 BFA, tsO45-G–YFP remained within the ER
compartment following the temperature shift, even in prolonged
time-course experiments (results not shown). These effects are
indistinguishable from those reported previously in Exo2-treated
BS-C-1 cells [18].
We then examined the effects of a 2 h Exo2 treatment on the
gross morphology of intracellular compartments using indirect
immunofluorescence (Figure 4). Since Exo2 blocks secretory
cargo export from the ER, the distribution of COPII (coatomer
protein II) coat proteins was examined using antibodies raised
against the Sec31A (Figure 4) and Sec24C components (results
not shown). Their location and the rate of their recycling on and
off the ER membrane (measured using EGFP–Sec24C or EGFP–
Sec31A) remained unchanged following Exo2 treatment (results
not shown). EEs (labelled using EEA1) also showed no change
in gross morphology or distribution (Figure 4). However, Exo2
treatment did stimulate a redistribution of giantin from the Golgi to
the ER/ERGIC, although ERGIC-53 itself was relocated to the ER
and COPI was released from the Golgi and ERGIC membranes to
a cytosolic location. These effects of Exo2 are consistent with the
disruption of the COPI-dependent pathway and Golgi apparatus
as observed previously [18]. Unexpectedly, and in contrast with
a previous report [18], the TGN marker golgin-97 redistributed
from a classic juxtanuclear position to a peripheral localization
in the presence of Exo2 (Figure 4). These results suggest that, in
HeLa cells, Exo2 may have very similar effects on the Golgi
and the TGN as BFA. This was examined in more detail using
time-lapse microscopy.
First, we followed the distribution of a EGFP-tagged marker of
the Golgi apparatus, NAGFP (EGFP fused to the Golgi retention
signal of N-acetylglucosaminyltransferase I) [40]. As expected,
BFA caused a complete and rapid redistribution of NAGFP to
the ER (Figure 5A and Supplementary Movie S1 at http://www.
c© The Authors Journal compilation c© 2008 Biochemical Society© 2008 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.
476 R. A. Spooner and others
Figure 4 Steady-state localization of endomembranes is perturbed by Exo2
HeLa cells were incubated with 50 μM Exo2 for 2 h at 37◦C, followed by fixing and processing
for immunofluorescence with antibodies specific for the proteins indicated. Cells were then
imaged using confocal microscopy; images shown represent maximum intensity projections of
ten z slices through each sample. Control is untreated cells incubated with DMSO.
BiochemJ.org/bj/414/bj4140471add.htm). A similar rapid re-
distribution occurred in ∼90% of Exo2-treated cells. Secondly,
given the discrepancy between our observations of an Exo2-medi-
ated disruption of the TGN, as visualized through a redistribution
of golgin-97, and a published report showing that Exo2 has no
effect on the TGN marker TGN46 in monkey BS-C-1 cells [18],
we examined the location of these two proteins in time-course
experiments. In HeLa cells, Exo2 promoted a redistribution of
TGN46 and golgin-97 from a juxtanuclear location to a peripheral
pattern within 60 min (Figures 5B and 5C). Interestingly, at later
time points (e.g. 300 min), we consistently observed a sub-popul-
ation of cells in which the original juxtanuclear localization be-
came more prominent (Figures 5B and 5C, arrows). After a
1 h incubation with Exo2, 90% of cells showed disrupted
TGN46 localization (Figure 6). These results are consistent
with the known effects of BFA on TGN morphology where the
redistribution of TGN markers is also non-uniform [7,8,41].
Next, we compared the effects of Exo2 in HeLa and BS-C-1
cells (see Supplementary Figure S1 at http://www.BiochemJ.org/
bj/414/bj4140471add.htm). We found that in BS-C-1 cells the
TGN becomes dispersed, but a remnant remains at the classical
juxtanuclear position following Exo2 treatment. This indicates
a partial but incomplete dispersion of the TGN in BS-C-1 cells
treated with Exo2 and clarifies the difference between our results
and the results published previously [18]. We then investigated
whether or not Exo2 treatment stimulates TGN–endosome fusion
in HeLa cells (see Supplementary Figure S2 at http://www.
BiochemJ.org/bj/414/bj4140471add.htm). TGN46 redistributed
after Exo2 treatment to structures localized near EEs. No fusion
was seen with these structures, late endosomes (stained with
CD63) nor lysosomes (labelled with LysoTracker). No plasma-
membrane co-localization was seen (results not shown).
Thus in both HeLa and BS-C-1 cells, the effects of Exo2 on
ERGIC and Golgi membranes are very similar to those of BFA, but
with respect to the TGN, there is a highly significant difference:
whereas BFA induces tubulation of the TGN [7], Exo2 does not.
The TGN is nevertheless dispersed by Exo2 in both cell types,
although there are cell-type-specific differences in the magnitude
of this response. In a fraction of the Exo2-treated HeLa cells, the
TGN staining pattern that was lost at early time points became
partly restored with increasing lengths of Exo2 incubation, which
may point to a recovery of the TGN over time. Thus the changing
STx cytotoxicity profile with time (Figure 2) might be explained
by a partial recovery of functional organelles.
Exo2 retards the ER delivery of STx in HeLa cells
Retrograde trafficking of STx can be monitored using a recom-
binant STxBsulf cargo containing an accessible sulfation site
that permits in vivo modification by the addition of 35SO42− in
a reaction catalysed by TPST [22,42]. In Exo2-treated cells,
we observed retarded kinetics of STxB sulfation following both
20 min treatment with STxBsulf (Figure 7A) and in a time course
of toxin treatment (Figure 7B). The overall level of protein
sulfation was reduced in Exo2-treated cells. Normalization of
results to total sulfation counts for each time point revealed a
delay of at least 60 min in reaching the sulfation compartment
following Exo2 treatment, with the peak of sulfation occurring
between 2–4 h in Exo2-treated cells compared with just 1 h in con-
trol cells (Figure 7C). Thus Exo2 treatment causes a delay in the
arrival of STxB to the sulfation compartment.
The site of this modification in mammalian cells has been
variously reported to be the trans-Golgi compartment (i.e. part
of the cisternal stack) or the TGN, which is directly apposed
to the trans-Golgi itself [22,43,44]. Since the sulfation assay
defines the arrival of cargo at a TPST-containing compartment, we
examined the cellular site of the two human TPST1 and TPST2
isoforms [45,46] in the presence and absence of Exo2. As available
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Figure 5 Perturbation of Golgi and TGN markers by Exo2
(A) HeLa cells transfected with NAGFP were incubated in the presence of either BFA (upper panels) or 50 μM Exo2 (lower panels) at 37◦C and imaged using time-lapse microscopy immediately
after the addition of inhibitors. Still images at 0, 10, or 20 min after the addition of inhibitors are shown. The asterisk (∗) marks a Golgi apparatus that is relatively Exo2-resistant. (B and C)
Cells were incubated with either DMSO or 50 μM Exo2 at 37◦C and fixed after incubation for various time points (0, 5, 60, 180 and 300 min) and processed for immunofluorescence using
antibodies directed against TGN46 (B) or golgin-97 (C). Note that the panels in (B) and (C) are from the same cells, double-labelled for these markers. Arrows indicate re-emergence of juxtanuclear
staining.
antibodies were not effective for in vivo immunolabelling (results
not shown), we generated C-terminal EGFP-tagged versions for
expression and imaging. TPST1/2 are type I integral membrane
proteins, and so C-terminal tagging circumvents any potential
problems of the tag interfering with the N-terminal signal
sequence.
Transient expression of either TPST1–EGFP or TPST2–EGFP
at low levels in HeLa cells resulted in their localization to a
juxtanuclear pool consistent with either Golgi or TGN membranes
(Figure 8A), with a small amount in peripheral punctae. Following
incubation with BFA or Exo2, the bulk of TPST1–EGFP and
TPST2–EGFP was seen to relocate to the ER, although some
peripheral punctate labelling remained (Figure 8A). Subsequent
results are shown for TPST1–EGFP, but indistinguishable results
were seen using TPST2–EGFP (results not shown). In the pres-
ence of Exo2, the majority of TPST1–EGFP co-localized with
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Figure 6 Quantification of organelle disruption by Exo2
Cells processed as in Figure 4 were quantified for TGN46 localization. The histogram shows the
percentage of cells with disrupted TGN46 localization at the indicated time points after addition
of DMSO (white bars) or Exo2 (grey bars). Results are means +− S.D.
Figure 7 Exo2 treatment retards the sulfation of STxB chain
(A) Treatment of HeLa cells with Exo2 prevents sulfation of STxBsulf (arrowhead) 20 min
post-internalization. Cells were pre-treated with 50 μM Exo2 for 30 min at 37◦C, incubated
with STxB on ice and then further incubated for 20 min in the presence of Exo2 (see the
Experimental section).(B) Time courses of STxB sulfation (arrowhead). Upper panel: during
DMSO treatment; lower panel: during Exo2 treatment. Cells were pre-treated with 50 μM Exo2
for 30 min at 37◦C, incubated with STxB on ice and then further incubated for 0, 20, 40, 60, 120,
180 and 240 min in the presence of Exo2 (see the Experimental section). (C) Relative STxB sulf-
ation profiles after DMSO () and Exo2 treatment (; 50 μM Exo2 ), normalized to general
sulfation levels.
Figure 8 TPST1–EGFP predominantly localizes to the trans-Golgi
(A) TPST1–EGFP or TPST2–EGFP transiently expressed in HeLa cells at low levels of expression
were imaged after treatment in the absence or presence of DMSO, BFA and 50 μM Exo2 for 2 h
at 37◦C as indicated. Scale bar, 20 μm. (B) HeLa cells transiently expressing TPST1–EGFP
were treated for 1 h at 37◦C with DMSO or 50 μM Exo2 diluted in culture medium, fixed
and immunolabelled using the indicated antibodies. Typically, 10 stacks were acquired through
the sample. For calnexin labelling, a single z slice is shown and the arrowhead points to the
nuclear envelope. Other images shown represent the maximum projection of the z stacks.
Indistinguishable results were obtained for TPST2–EGFP (results not shown). Scale bar, 5 μm.
calnexin, a marker of the ER; some peripheral punctate localiz-
ation remained, but this pool of TPST1–EGFP did not co-
localize with any marker tested, including TGN46 and golgin-97
(Figure 8B). Double-labelling experiments revealed that,
at steady-state, TPST1–EGFP partially overlaps with both GalT,
a cis-medial Golgi marker, and TGN46, a definitive marker for the
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Figure 9 TPST1–EGFP co-localizes with GalT in nocodazole-induced mini Golgi stacks
TPST1–EGFP was expressed in HeLa cells which, where indicated, were incubated in the presence of nocodazole before fixing and immunolabelling for the Golgi marker GalT or the TGN marker
TGN46 as indicated. Indistinguishable results were obtained using TPST2–EGFP (results not shown). Scale bar, 20 μm. Insets show 2 × enlargements of the boxed regions. Note the absence of
co-localization with TGN46.
TGN [47,48] (Figure 9). To examine this in more detail, cells were
treated with nocodazole to depolymerize microtubules and scatter
the Golgi apparatus; scattered Golgi elements in this experiment
retain their cis–trans polarity [49]. These Golgi elements showed
a clear distinction between the localization of TPST1–EGFP and
TGN46, with a higher degree of co-localization seen between
GalT and TPST1–EGFP (Figure 9) and golgin-97 (results not
shown). Similar results were obtained by co-staining for GM130
and TPST-1 (results not shown). The identity of the peripheral
punctae is not known, although some but not all co-localize with
GalT, indicating they are scattered Golgi elements. Although these
punctae were positive for TPST1–EGFP in BFA-treated cells, they
were shown not to stain for EEA1, CD63 or ERGIC-53, indicating
that they do not represent early- or late-endosomal membranes or
the ERGIC compartment respectively (results not shown). Exo2
did not induce tubulation of the TGN in these cells, nor in live
cells expressing low levels of TPST–EGFP (results not shown).
Together these results indicate that in HeLa cells, the majority
of TPST is normally localized in the GalT-containing trans-Golgi
cisternae, and that upon Exo2 treatment, TPST is relocalized to
the ER. Thus the most rational explanation for the kinetic delay
in sulfation of STxBsulf (Figure 7) is that the sulfation assay
measures the delivery of STxB from the dispersed TGN and/or
endosomes to the ER.
c© The Authors Journal compilation c© 2008 Biochemical Society© 2008 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.
480 R. A. Spooner and others
Figure 10 BFA, but not Exo2, induces tubulation of early endocytic compartments
Cells loaded with fluorescent transferrin for 5 min at 37◦C were imaged by time-lapse microscopy in the presence of either BFA (top panels) or 50 μM Exo2 (lower panels). The time-lapse sequence
is included as Supplementary Movie S1 (see http://www.BiochemJ.org/bj/414/bj4140471add.htm), and still images taken at 0, 2 and 4 min after addition of BFA or Exo2 are shown. Note the extensive
tubulation of EEs following the addition of BFA, which are never observed following the addition of Exo2. Scale bar, 20 μm.
Exo2 blocks delivery of STx to the disrupted TGN of HeLa cells
Next, we examined the effect of Exo2 on the early-endosomal
compartment, through which STx normally traffics en route
to the TGN. A well-characterized effect of BFA is its ability to
cause the tubulation of EEs [7,8]. To test the effects of Exo2
on EE tubulation, cells were loaded with fluorescent transferrin
for 5 min, before adding DMSO, BFA or Exo2, and then imaged
immediately. Figure 10 reveals that untreated cells show a classic
distribution of transferrin in small punctae throughout the cell
(0 min time point). On addition of DMSO, these punctae do not
appear to change (results not shown). However, on addition of
BFA, the expected extensive tubulation of this EE compartment
(2 and 4 min time points) was observed [7]. In stark contrast,
Exo2 did not result in tubulation of endosomes, and cells appeared
to be indistinguishable from controls (Figures 4 and 10, bottom
panels). Time-lapse data from the experiments shown in Figure 10
are included in Supplementary Movie S1 (at http://www.
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Figure 11 Exo2 inhibits transit of STxB to the TGN
(A) HeLa cells were pre-treated with 50 μM Exo2 for 30 min at 37◦C, stained with Cy3-labelled STxB (red) on ice followed by warming to 37◦C for 90 min in the presence of Exo2. Cells were fixed
and immunolabelled with antibodies against TGN46 (green) and the TfR (blue). Extensive co-localization of TGN46 and STxB is seen in control cells (arrows), but not in Exo2-treated samples. STxB
also did not co-localize with TGN46 at either 45 min or 120 min at 37◦C (results not shown) in Exo2-treated cells. TfR labelling is also seen in close proximity to that of STxB and TGN46 in controls,
but not in Exo2-treated cells. Images shown are maximum intensity projections of 10 confocal z slices (pinhole at 1 Airy unit) that have been processed in Volocity 4.3 (Improvision) with a low-pass
noise filter. Scale bar, 10 μm. (B) Enlargements (×4) of the boxed regions.
BiochemJ.org/bj/414/bj4140471add.htm). In order to confirm the
efficacy of Exo2 in these experiments, cells were transfected with
a plasmid expressing NAGFP [40] prior to loading with trans-
ferrin. This enabled us to confirm that the Golgi structure was
disrupted, despite there being no tubulation of transferrin-positive
EEs in the same cells (results not shown). Thus while the effects
of Exo2 on ERGIC and Golgi membranes are very similar to
those of BFA in HeLa cells (see above), there are striking differ-
ences in their effects on the TGN and EEs. Even after lengthy
incubations (2 h) with high concentrations of Exo2, we could
detect no endosomal tubulation (results not shown).
We then examined the arrival of toxin to the TGN following
its application at the cell surface (Figure 11). Since TPSTs
are redistributed to the ER by Exo2 treatment, they cannot be
regarded as a reliable marker of TGN arrival in Exo2-treated
cells. We therefore monitored the transport of Cy3-labelled STxB
into TGN46-positive compartments. In control cells, 90 min
after exposure to STxB, immunofluorescence labelling showed
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extensive co-localization with TGN46 (Figure 11). At the same
time, in Exo2-treated cells, no significant co-localization with
TGN46 was noted. This suggests that the primary block in
retrograde transport of STx induced by Exo2 treatment lies
between an endosomal compartment and the TGN, with perhaps a
further block between the TGN and the Golgi caused by collapse
of the Golgi stack into the ER. Thus at all the time points tested
following Exo2 treatment, STxB-labelled endosomes and the
TGN remain as distinct organelles; we also note that STxB and
transferrin labelling remains distinct following Exo2 incubation,
indicating that STxB and transferrin either label distinct domains
of the same endosome or, more likely, they label distinct endo-
somes. We also note that the juxtanuclear clustering of the TfR
in control cells is perturbed following incubation with Exo2. This
hints at the possible perturbation of centripetal movement of EEs
in Exo2-treated cells, possibly through inhibition of minus-end-
directed microtubule-based transport.
DISCUSSION
Our results show that Exo2 has overlapping but distinct effects
on membrane trafficking in mammalian cells compared with the
widely used compound BFA. BFA and Exo2 appear indisting-
uishable in terms of disrupting anterograde traffic from the ER to
the Golgi and in perturbing the juxtanuclear localization of the
Golgi stack. In contrast with a report published previously [18],
we also find that when the widely used HeLa epithelial cell line
is treated with Exo2, it causes dispersion of the TGN, like BFA.
We note that there are cell-type differences in the severity of the
Exo2-induced effect, with a less pronounced effect on the TGN
in BS-C-1 cells. However, Exo2 does not cause the tubulation
that has been observed for some TGN markers when cells are
treated with BFA [7]; it does not induce tubulation of endosomes,
even after prolonged treatment, and it does not impede the
uptake of STx into endosomes. The major difference in cellular
morphological changes stimulated by the two reagents appears to
be that although BFA disrupts the cell at the level of the ER/Golgi
and the endosome/TGN interfaces, the major effects of Exo2
appear largely to be restricted to the TGN, Golgi stack and the
ER. Upon closer examination, we find that Exo2 treatment has
subtle effects at the endosomal level, inhibiting the transfer of
internalized STxB to the TGN.
The morphological description of the Exo2 phenotype that we
provide is complemented by inspection of the retrograde-uptake
pathway of STx and STxB, its cell-binding B chain. These proteins
provide useful probes to test the functionality of retrograde trans-
port routes, since they normally traffic via the EEs, TGN and Golgi
to the ER [22,25,50], where the A chain of the holotoxin retro-
translocates across the ER membrane to damage target ribosomes.
Thus inhibition of protein synthesis can be used to monitor suc-
cessful negotiation of the retrograde-transport pathway, and sulf-
ation can be used to measure the arrival of STxB in the sulfation
compartment. In this way, the sulfation of a modified CTx and
the activation of its cytosolic target, adenylyl cyclase, in Exo2-
treated epithelial cells in which the integrity of the TGN was
retained, led to the proposal of a direct and efficient TGN-to-ER
lipid-dependent sorting pathway [18]. CTx and STx bind cell-
surface ganglioside GM1 and Gb3 respectively, and normally
traffic via EEs and the TGN to the ER lumen in association with
detergent-resistant lipid microdomains, in a manner that is not
dependent on either KDEL receptors or COP1 transport inter-
mediates [23–26]. Although much is known about their intracellu-
lar trafficking, it remains unclear whether the lipid-transport
pathway is utilized only by ganglioside-binding proteins or
whether it is also exploited by proteins that interact with other
microdomain-enriched lipids. We therefore tested the effects of
Exo2 on the uptake of STx. Since Exo2 did not disrupt the lipid-
dependent sorting pathway believed to be used by proteins such
as STx and CTx [18], it was anticipated that the entry of STx
would be unaffected.
Unexpectedly, the present paper reveals that the transport of
STx in HeLa cells is very severely hampered by Exo2 treatment,
particularly following short (1–2 h) challenges with toxin. The
magnitude of these effects after a 1 h toxin challenge (∼150-fold)
shows that less than 1% of the toxin that reaches the cytosol in
Exo2-untreated cells reaches the cytosol in Exo2-treated cells.
This would indicate that even in the ∼10% of Exo2-treated
cells that retain unchanged Golgi and TGN markers (Figure 5),
retrograde transport through these structures is highly compro-
mised. However, toxicity is not completely abrogated (as it is
with BFA), indicating that the Exo2 block is either incomplete,
permitting some residual retrograde transport, or that a much less
efficient transport pathway operates from other compartments in
the absence of a Golgi stack. Either way, the effects of Exo2 on
STx uptake are markedly different from the reported effects
on CTx uptake [18].
The observed delay in STx sulfation reported in the present
paper (Figure 7) is consistent with a blockade in transport between
the endosomes and TGN. However, a little-cited pleiotropic effect
of BFA is the complete inhibition of the Golgi uptake of the
activated substrate of TPST, PAPS (adenosine 3′-phosphate 5′-
phosphosulfate) [51] and a total abrogation of protein sulfation
[52]. The fact that the TPSTs continue to act upon their substrates
in the presence of Exo2, as shown in the present paper and
elsewhere [18], may therefore reflect either their relocation to
the ER membrane or the action of TPST in the fragmented
TGN, although we cannot detect its presence in the TGN in the
experiments described here (Figure 8). Either way, our results
point to difficulties in transporting STx from endosomes in
Exo2-treated cells. This led us to examine the endosome/TGN
interface more closely (Figures 10 and 11). The results point
to an unexpected divergence in toxin trafficking. Although CTx
and STx are normally transported to the Golgi along pathways
generally considered to be indistinguishable [53], Exo2 has
brought to light some subtle differences in their routing. Although
the Exo2-induced collapse of the Golgi stack into the ER does
not affect the transport of CTx [18], which can presumably
bypass this organelle altogether, Exo2 severely impedes the
uptake of STx. This suggests that STx is largely constrained
to a transport pathway through the Golgi. However, the subtle
spatial rearrangement of the endosome system induced by Exo2
treatment, and the failure of STx to efficiently access TGN46-
positive compartments in Exo2-treated cells, perhaps points to an
earlier separation of the toxin-trafficking routes, with a block at
the EEs/TGN interface operating for STx, but not for CTx. The
major target of Exo2 may therefore be a molecule involved in
both early-endosomal delivery to the TGN and TGN access to
the Golgi stack, or may be related proteins operating at both of
these sites. Clearly the identification of the target(s) of Exo2 is an
important next step.
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The secretion inhibitor Exo2 perturbs trafficking of Shiga toxin between
endosomes and the trans-Golgi network
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Figure S1 Effects of Exo2 on BS-C-1 cells
BS-C-1 cells (A.T.C.C. CCL-26) were treated with DMSO (Control) or with 50 μM Exo2 for 2 h at 37◦C, fixed, stained with the indicated antibodies and imaged on a wide-field microscope. The
maximum intensity projection of at least ten z slices through the sample is shown. Arrows indicate examples of TGN remnants visible in BS-C-1 cells treated with Exo2 that retain their juxtanuclear
position: TGN dispersion is less pronounced than in HeLa cells. Scale bar, 20 μm.
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Figure S2 Localization of TGN46 in Exo2-treated cells
HeLa cells were treated with 50 μM Exo2 for 2 h at 37◦C, diluted in culture medium, fixed and processed for immunofluorescence with the indicated antibodies. Maximum projections of at least
ten z stacks are shown. Exo2-induced altered TGN structures appeared to localize close to the EE (labelled by EEA1), but not to merge with the late endosomal (labelled with CD63) or lysosomal
compartments (labelled by LysoTracker Red). Merge column (far right-hand side) shows DAPI (4′ ,6-diamidino-2-phenylindole; blue),TGN46 (green), and staining for calnexin, EEA1, CD63 and
LysoTracker Red is shown in red as indicated. Scale bar, 10 μm.
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